Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00164437 · ClinicalTrials.gov registry record · Phase 2

CD-ROM Intervention for Prostate Cancer Screening

A Phase 2 study of Prostate Cancer, sponsored by Centers for Disease Control and Prevention.

Completed
Registry status
Phase 2
Development phase
554
Enrollment target
1
Study location

NCT00164437: Completed Phase 2 study of Prostate Cancer, sponsored by Centers for Disease Control and Prevention.

NCT00164437 is a Phase 2 study of Prostate Cancer that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 554 participants, roughly in line with the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00164437, a Phase 2 study of Prostate Cancer, has completed, sponsored by Centers for Disease Control and Prevention.

COMPLETED
Registry status
Phase 2
Development phase
554 participants
Enrollment target
1
Study location

Study Summary

The study populations consist of a sample of the patient population (men aged 40-79 years) of a large, group model HMO and a community sample of men age 50-79. Follow-up interviews of men randomly assigned to the intervention and control groups are being conducted by telephone to assess issues related to prostate cancer screening and the men's use of the CD-Rom educational intervention.

Conditions Studied

Interventions

  • BEHAVIORAL educational CD-ROM

Study Locations (1)

Colorado

  • University of Colorado Health Sciences Center - Denver

Trial Details

FieldValue
Enrollment Target 554 participants
Start Date 2002-09
Est. Completion 2004-09
Phase Phase 2

What the finished NCT00164437 record still lists

NCT00164437 is an interventional study that assigns participants to a tested intervention. The registered 554 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which educational CD-ROM is the first listed.

NCT00164437 reports a single indexed study location in Colorado.

Frequently Asked Questions

What is clinical trial NCT00164437 about?

NCT00164437 is a clinical study titled "CD-ROM Intervention for Prostate Cancer Screening". The study populations consist of a sample of the patient population (men aged 40-79 years) of a large, group model HMO and a community sample of men age 50-79. Follow-up interviews of men randomly assigned to the intervention and control groups are being conducted by telephone to assess issues relat...

What is the current status of trial NCT00164437?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 554 participants. The study started on 2002-09. Estimated completion is 2004-09.

What conditions does trial NCT00164437 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT00164437?

The interventions under investigation include: educational CD-ROM (BEHAVIORAL).

Who is sponsoring clinical trial NCT00164437?

This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00164437 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00164437's enrollment target sits among peer trials

554 101st of 735 higher than 635 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05786924 · 554 participants · Phase 1

    Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  • NCT06799000 · 555 participants · Phase 3

    A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

  • NCT06840392 · 555 participants · Phase 3

    A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

  • NCT06074588 · 556 participants · Phase 3

    Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00164437, the US trial registry maintained by the National Library of Medicine. NCT00164437 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.